FKONCO

DSP Merrill Lynch Limited has submitted to the Exchange a copy of the Supplement to the Second Corrigendum ("Corrigendum") to the Public Announcement issued pertaining to the delisting offer made by Fresenius Kabi (Singapore) Pte Ltd to the public shareholders of Fresenius Kabi Oncology Limited ("Company") ("Delisting Offer").

DSP Merrill Lynch Limited has informed the Exchange regarding the Second Corrigendum ("Corrigendum") to the Public Announcement issued pertaining to the delisting offer made by Fresenius Kabi (Singapore) Pte Ltd to the public shareholders of Fresenius Kabi Oncology Limited ("Company") ("Delisting Offer").

DSP Merrill Lynch Limited has informed the Exchange regarding Corrigendum ("Corrigendum") to the Public Announcement issued pertaining to the delisting offer made by Fresenius Kabi (Singapore) Pte Ltd to the public shareholders of Fresenius Kabi Oncology Limited ("company") ("Delisting Offer").

Members of the Exchange are hereby informed that the name of Dabur Pharma Limited shall be changed to Fresenius Kabi Oncology Limited and the trading symbol of the Company be changed from DABURPHARM to FKONCO w.e.f. February 19, 2009.

Dabur Pharma Limited has informed the Exchange that with a view to provide better and efficient services to investors, the management has decided to change the existing Registrar and Share transfer agent i.e. M/s. MCS Limited, Sri Venkatesh Bhavan, W-40 Okhla Industrial Area, Phase II, New Delhi - 110020 to M/s. Karvy Computershare Private Limited, Plot no.17-24, Vithalrao Nagar, Madhapur, Hyderabad - 500086 w.e.f. January 12, 2008. The Company has made a request to MCS Limited, New Delhi for their NOC.